This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Stephan Fischer, Ph.D.
Founder CEO and CSO at IcanoMAB GmbH


Stephan Fischer obtained his PhD in Microbiology from the Technical University of Munich. He has spent more than 25 years in the area of recombinant proteins and antibodies in various roles.He was a Post Doc at the European Molecular Biology Laboratory where he focused on protein structure research. At Boehringer Mannheim he developed technologies and products for Diagnostics and Pharma. Stephan was a member of the team that brought recombinant erythropoietin to the market and global project manager to take the thrombolytic reteplase from discovery to market launch in Europe and the US.After the acquisition of Boehringer Mannheim by Roche he took over various roles as a global manager and, in 2005, Stephan was promoted to a Senior VP for Biologics R&D within Roche Pharma Research in Penzberg, Germany. Besides his internal operational roles, he represented the company in a role to develop and establish international biosimilar policies.

In October 2010 he founded MAB Discovery GmbH in Neuried/Munich. Within 2 years, he created a new organisation with 20 FTEs to identify monoclonal antibodies with a novel approach.In April 2019 the operational unit in Munich/Neuried has been acquired by BioNTech. MABD continued its activities on their proprietary project pipeline. With funding from MAB Discovery, Stephan founded IcanoMAB GmbH in 2020 as a virtual company to further develop these assets. The CD40 agonist program is one of 9 projects.

Agenda Sessions

  • Fcγ-receptor-independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy